Medexus Pharmaceuticals Inc.
MEDXF
$2.39
$0.104.15%
OTC PK
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -107.64% | -83.40% | -26.19% | 1,150.00% | -39.42% |
| Total Depreciation and Amortization | 56.91% | 53.77% | 42.01% | 23.63% | 5.94% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -68.46% | -44.00% | -23.76% | -18.69% | 91.45% |
| Change in Net Operating Assets | 32.92% | -61.91% | -42.42% | 149.59% | -10.66% |
| Cash from Operations | -25.69% | -26.82% | -12.92% | 28.43% | 11.42% |
| Capital Expenditure | -54.55% | -228.00% | -411.11% | -266.00% | -127.59% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -179.75% | -48.87% | -3.59% | -1.96% | 53.60% |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -171.84% | 6.37% | -2,234.72% | -1,077.31% | -1,613.66% |
| Cash from Investing | -156.59% | -13.74% | -134.22% | -72.54% | -23.14% |
| Total Debt Issued | 45.45% | -- | -- | -- | -34.53% |
| Total Debt Repaid | -206.53% | 52.77% | 44.14% | 67.64% | 79.39% |
| Issuance of Common Stock | -- | -23.37% | -23.37% | -23.37% | -- |
| Repurchase of Common Stock | 97.87% | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 47.94% | 33.78% | 12.99% | -0.47% | -1.84% |
| Cash from Financing | 102.28% | 75.25% | 58.61% | 103.45% | 0.87% |
| Foreign Exchange rate Adjustments | 171.90% | -317.65% | 80.46% | -5,450.00% | -448.42% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 2,765.79% | 119.22% | 111.98% | 339.54% | 121.51% |